Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Income from Continuing Operations: 2017-2025

Historic Income from Continuing Operations for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to -$36.6 million.

  • Dianthus Therapeutics' Income from Continuing Operations fell 43.90% to -$36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$125.5 million, marking a year-over-year decrease of 87.03%. This contributed to the annual value of -$84.5 million for FY2024, which is 94.65% down from last year.
  • As of Q3 2025, Dianthus Therapeutics' Income from Continuing Operations stood at -$36.6 million, which was down 16.20% from -$31.5 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Income from Continuing Operations peaked at -$7.1 million during Q1 2023, and registered a low of -$36.6 million during Q3 2025.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$17.5 million (2024), whereas its average is -$20.5 million.
  • Data for Dianthus Therapeutics' Income from Continuing Operations shows a maximum YoY plummeted of 165.66% (in 2024) over the last 5 years.
  • Dianthus Therapeutics' Income from Continuing Operations (Quarterly) stood at -$10.1 million in 2022, then decreased by 4.57% to -$10.5 million in 2023, then tumbled by 165.66% to -$27.9 million in 2024, then tumbled by 43.90% to -$36.6 million in 2025.
  • Its Income from Continuing Operations stands at -$36.6 million for Q3 2025, versus -$31.5 million for Q2 2025 and -$29.4 million for Q1 2025.